Literature DB >> 10557056

Detection of MUM1/IRF4-IgH fusion in multiple myeloma.

S Yoshida1, N Nakazawa, S Iida, Y Hayami, S Sato, A Wakita, S Shimizu, M Taniwaki, R Ueda.   

Abstract

MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) gene has been identified as an oncogene transcriptionally activated by t(6;14)(p25;q32) chromosomal translocation in multiple myeloma (MM). The significance of this alteration in MM remains unknown, as it is not detectable by means of conventional cytogenetic analysis. To address this issue, we established diagnostic procedures based on pulsed-field gel electrophoresis (PFGE) analysis and double color fluorescence in situ hybridization (DCFISH) using DNA probes derived from the MUM1 and the immunoglobulin heavy chain (IgH) gene loci. Among a panel of 17 MM cell lines, three (17.6%) showed fusions between these two loci, which resulted in the juxtaposition of the MUM1 to the IgH 3' alpha-enhancer region by virtue of t(6;14) or insertion of the IgH sequences into the vicinity of the MUM1 gene and in the concomitant overexpression of the MUM1 mRNA. With similar results, fusions between MUM1 and IgH loci were observed by means of interphase DCFISH in eight (21.1%) out of the 38 MM cases, although no definite relationships between MUM1 status and specific clinical findings could be established.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10557056     DOI: 10.1038/sj.leu.2401563

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts.

Authors:  R Hrdlicková; J Nehyba; H R Bose
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

2.  Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

Authors:  Esther M Yoo; Kham R Trinh; Danh Tran; Alex Vasuthasawat; Juan Zhang; Bao Hoang; Alan Lichtenstein; Sherie L Morrison
Journal:  J Interferon Cytokine Res       Date:  2014-10-29       Impact factor: 2.607

Review 3.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

4.  Regulation of telomerase activity by interferon regulatory factors 4 and 8 in immune cells.

Authors:  Radmila Hrdlicková; Jirí Nehyba; Henry R Bose
Journal:  Mol Cell Biol       Date:  2008-12-01       Impact factor: 4.272

Review 5.  IRF4: Immunity. Malignancy! Therapy?

Authors:  Arthur L Shaffer; N C Tolga Emre; Paul B Romesser; Louis M Staudt
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

6.  IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Authors:  Sensen Zhang; Jiaren Xu; Shuang Wu; Rong Wang; Xiaoyan Qu; Wenjun Yu; Jiangyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2013-05-12       Impact factor: 3.064

7.  Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.

Authors:  Christina A Ortmann; Andreas Burchert; Katharina Hölzle; Andreas Nitsche; Burghardt Wittig; Andreas Neubauer; Manuel Schmidt
Journal:  Nucleic Acids Res       Date:  2005-12-07       Impact factor: 16.971

Review 8.  Molecular interactions of IRF4 in B cell development and malignancies.

Authors:  Srinivasan Sundararaj; Marco G Casarotto
Journal:  Biophys Rev       Date:  2021-08-13

9.  Implication of IRF4 aberrant gene expression in the acute leukemias of childhood.

Authors:  Maria Adamaki; George I Lambrou; Anastasia Athanasiadou; Marianna Tzanoudaki; Spiros Vlahopoulos; Maria Moschovi
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

10.  MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Authors:  Masato Ito; Shinsuke Iida; Hiroshi Inagaki; Kazuya Tsuboi; Hirokazu Komatsu; Motoko Yamaguchi; Naoya Nakamura; Ritsuro Suzuki; Masao Seto; Shigeo Nakamura; Yasuo Morishima; Ryuzo Ueda
Journal:  Jpn J Cancer Res       Date:  2002-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.